Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target lowered by analysts at Royal Bank of Canada from $24.00 to $20.00. They now have an "outperform" rating on the stock.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target lowered by analysts at Leerink Partners from $19.00 to $18.00. They now have an "outperform" rating on the stock.
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights